ERBB2 and colorectal cancer: The Epidermal Growth Factor Receptor (EGFR)-targeting monoclonal antibodies (mAbs) cetuximab and panitumumab have been widely used for treatment of KRAS wild-type colorectal cancer, whereas the HER2-targeting antibody trastuzumab has been successful in HER2-amplified breast cancers1,2.